Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialYolanda Barbáchano, Ian Chau, David Cunningham et al.|The Lancet Oncology|2013Cited by 728
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S. Fuchs, Francesco Di Costanzo, Eric Van Cutsem et al.|The Lancet Oncology|2019Cited by 282
A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).Tom Samuel Waddell, David Cunningham, Ian Chau et al.|Journal of Clinical Oncology|2012Cited by 49